|
|
Viread (Tenofovir)
| Brand Name: |
Viread |
| Generic Name: |
Tenofovir disoproxil fumarate, TDF |
| Adult Single Dose: |
One 300-mg tablet (once a day) |
| Food & Liquid Restrictions: |
None |
| Drug Class: |
NRTI |
The Basics
- An Overview of Viread (Tenofovir) (Regularly Updated)
To read PDF, click here
From U.S. National Institutes of Health
- Viread (Tenofovir Disoproxil Fumarate, TDF) (January/February 2008)
To read PDF, click here
In Positively Aware, from Test Positive Aware Network
- Viread (Tenofovir) (September 28, 2007)
Basic information on dosing schedules and side effects.
From U.S. Department of Veterans Affairs
- Tenofovir (Viread) (July 23, 2007)
To read PDF, click here
From AIDS InfoNet
- Patient Information About Viread (Tenofovir) (PDF) (May 2007)
From Gilead Sciences, Inc.
- Tenofovir (Viread) (August 15, 2006)
From AIDS Treatment Data Network
- Viread (Tenofovir) (November 2005)
To read PDF, click here
From The Center for AIDS
- Drug Interactions: Tenofovir (August 2004)
From Project Inform
- Gilead's Viread International Access Program (May 2003)
In GMHC Treatment Issues, from Gay Men's Health Crisis
- Tenofovir: New Kind of Anti-HIV Drug Gets Approved (March 2002)
In Project Inform Perspective, from Project Inform
- Tenofovir DF 300 mg Consistently Demonstrates Anti-HIV Activity Regardless of Baseline Demographic Characteristics in Antiretroviral Experienced HIV-1-Infected Patients (October 29, 2001)
In 8th European Conference on Clinical Aspects and Treatment of HIV-Infection, from The Body PRO
- FDA Briefing Documents on Tenofovir (October 3, 2001)
From U.S. Food and Drug Administration
- Position Paper on NDA 21-356 for Gilead Sciences' Viread Brand Tenofovir Disoproxil Fumarate (October 3, 2001)
In TAGline, from Treatment Action Group
- New Drugs in Development: Very Viread (Fall 2001)
A look at the drug's indications, resistance profile and some clinical trial results.
To read PDF, click here
In CRIA Update, from AIDS Community Research Initiative of America
News
- Gilead Sciences May Lose Patent for Viread (January 25, 2008)
Looser patent laws could mean generic version of Tenofovir to come.
In Housing Works AIDS Issues Update, from Housing Works
- U.S. Patent Agency to Review Gilead's Claim on Tenofovir (July 20, 2007)
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention
- Gilead Lowers Its No-Profit Drug Prices for Truvada, Viread (August 30, 2005)
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention
- Viread (Tenofovir Disoproxil Fumarate) Labeling Revision (May 13, 2005)
Among the revisions is updated information regarding drug resistance and long-term effects on bone mineral density.
From U.S. Food and Drug Administration
- Warning on Two Specific 3-Drug Regimens: Viread + Videx + Either Sustiva or Viramune (November 23, 2004)
A brief comment on the recently issued warning that both regimens frequently fail.
In AIDS Treatment News, from AIDS Treatment News
- Two New Fixed-Dose Combinations Approved (August 2, 2004)
From U.S. Food and Drug Administration
- Food and Drug Administration to Expedite Decision on Emtricitabine/Tenofovir Pill (May 18, 2004)
In Kaiser Daily HIV/AIDS Report, from Henry J. Kaiser Family Foundation
- Drug Development News: Fixed-Dose Combinations (May/June 2004)
The Food and Drug Administration's fast-track approval process for fixed-dose combinations is about to bear fruit.
In GMHC Treatment Issues, from Gay Men's Health Crisis
- Gilead Sciences First-Quarter Profits Driven by Increase in Sales of Antiretroviral Viread (April 26, 2004)
In Kaiser Daily HIV/AIDS Report, from Henry J. Kaiser Family Foundation
- Atazanavir (Reyataz): New Recommendations if Combined With Tenofovir (Viread) -- and Warning on Viagra, Cialis, and Levitra (March 26, 2004)
New warnings on drug-drug interactions are noted in the prescribing information for atazanavir.
In AIDS Treatment News, from AIDS Treatment News
- Revised Labeling for Viread (Tenofovir Disoproxil Fumarate) 300 mg Tablets (November 4, 2003)
From U.S. Food and Drug Administration
- Gilead Warns Against Use of Triple-NRTI Regimen 3TC, ddI, Tenofovir (October 14, 2003)
To read PDF, click here
From U.S. Food and Drug Administration
- Atazanavir/Tenofovir Combo Should Be Boosted With Ritonavir (August 8, 2003)
From U.S. Food and Drug Administration
- FDA Orders Gilead for Second Time to Stop Downplaying Risks, Inflating Benefits of Antiretroviral Drug Viread (August 8, 2003)
In Kaiser Daily HIV/AIDS Report, from Henry J. Kaiser Family Foundation
- U.S. Approves Emtriva; Gilead Hopes Viread/Emtriva Combo Will Compete With Combivir (July 3, 2003)
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention
- European Union Gives Thumbs-Up to Tenofovir Use in Treatment-Naive Patients (May 28, 2003)
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention
- HIV-Positive Man Dies of Kidney Failure and Lactic Acidosis Due to Tenofovir/ddI Interaction (April 8, 2003)
From aidsmap.com
- Three French Cases of Tenofovir Kidney Toxicity Reported Amongst HIV-Positive Patients (April 8, 2003)
From aidsmap.com
- Gilead Offers Tenofovir to Developing Countries at Cost (April 4, 2003)
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention
- New Safety Information -- Viread Co-Administration With Videx (September 30, 2002)
From U.S. Food and Drug Administration
- ddI-Tenofovir Interaction Warning (PDF) (May 7, 2002)
From Bristol-Myers Squibb Company
- More Uses for Tenofovir? (January 25, 2002)
The drug's usefulness in pregnant women, as a microbicide or as first-line therapy has yet to be thoroughly investigated.
To read PDF, click here
In AIDS Treatment News, from AIDS Treatment News
- Nutrient Deficiency Associated With New HIV Medication (December 2001)
In Survival News, from AIDS Survival Project
- Tenofovir (Viread), First Novel Antiviral Agent in Six Years, Approved by FDA (November 2001)
In TAGline, from Treatment Action Group
- FDA Approves Viread for HIV-1 Infection (October 29, 2001)
From U.S. Food and Drug Administration
- Tenofovir Approved: Broad Indication (October 26, 2001)
To read PDF, click here
In AIDS Treatment News, from AIDS Treatment News
- Tenofovir: FDA Hearing on Important New Antiretroviral (October 19, 2001)
To read PDF, click here
In AIDS Treatment News, from AIDS Treatment News
- Expanded Access to Tenofovir (October 9, 2001)
From Canadian AIDS Treatment Information Exchange
- Activists Call for Immediate Approval of Viread Tenofovir DF (October 3, 2001)
In TAGline, from Treatment Action Group
- Tenofovir: FDA Hearing October 3, Public Comment Deadlines September 26 (August 24, 2001)
To read PDF, click here
In AIDS Treatment News, from AIDS Treatment News
- Tenofovir DF on the Horizon (August/September 2001)
In Positive Living, from AIDS Project Los Angeles
- Tenofovir: Gilead Applies for Approval; Expanded Access Liberalized (May 11, 2001)
To read PDF, click here
In AIDS Treatment News, from AIDS Treatment News
- Gilead Provides Expanded Access Program for Tenofovir (March 2001)
To read PDF, click here
In Project Inform Perspective, from Project Inform
- Tenofovir Expanded Access (Spring 2001)
To read PDF, click here
In CRIA Update, from AIDS Community Research Initiative of America
- Tenofovir DF Expanded Access (February 23, 2001)
In AIDS Treatment News, from AIDS Treatment News
- Early Access Program Opened for Nucleotide Analogue Tenofovir (February 22, 2001)
In STEP Ezine, from Seattle Treatment Education Project
- PMPA (Tenofovir) -- Access Programs in Development (December 1999)
In Body Positive, from Body Positive
- Tenofovir Compassionate Use Program (September/October 1999)
In GMHC Treatment Issues, from Gay Men's Health Crisis
- PMPA in Perspective (December 1, 1995)
In AIDS Treatment News, from AIDS Treatment News
|
|
